Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2026-05-07
Original market date: See footnote 1
2026-05-07
Product name:
RECARBRIO
Description:
SINGLE-USE VIAL
DIN:
02565323
Product Monograph/Veterinary Labelling:
Date:
2026-01-30
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
MERCK CANADA INC
16750 Route Transcanadienne
Kirkland
Quebec
Canada
H9H 4M7
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
3
Schedule(s):
PRESCRIPTION
Anatomical Therapeutic Chemical (ATC): See footnote 4
J01DH56 IMIPENEM, CILASTATIN AND RELEBACTAM
Active ingredient group (AIG) number:See footnote5
0368096001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| CILASTATIN (CILASTATIN SODIUM) | 500 MG / VIAL |
| IMIPENEM | 500 MG / VIAL |
| RELEBACTAM | 250 MG / VIAL |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.